TY - JOUR
T1 - Metastatic profiling of HER2-positive breast cancer cell lines in xenograft models
AU - Han, Yuxuan
AU - Azuma, Kazushi
AU - Watanabe, Shinya
AU - Semba, Kentaro
AU - Nakayama, Jun
N1 - Funding Information:
This study was supported by JSPS KAKENHI (Grant No. 18K16269: Grant-in-Aid for Early-Career Scientist to JN; Grant No. 20J01794, Grant-in-Aid for JSPS fellows to JN; Grant No. 20J23297, Grant-in-Aid for JSPS fellows to YH) and partially supported by the grants for translational research programs from Fukushima Prefecture (SW and KS).
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature B.V.
PY - 2022/6
Y1 - 2022/6
N2 - Most studies on breast cancer metastasis have been performed using triple-negative breast cancer cells; thus, subtype-dependent metastatic ability of breast cancer is poorly understood. In this research, we performed intravenous injection (IVI) and intra-caudal arterial injections using nine human epidermal growth factor receptor-2 (HER2)-positive breast cancer cell lines for evaluating their metastatic abilities. Our results showed that MDA-MB-453, UACC-893, and HCC-202 had strong bone metastatic abilities, whereas HCC-2218 and HCC-1419 did not show bone metastasis. HER2-positive cell lines could hardly metastasize to the lung through IVI. From the genomic analysis, gene signatures were extracted according to the breast cancer subtypes and their metastatic preferences. The UACC-893 cell line was identified as a useful model for the metastasis study of HER2-positive breast cancer. Combined with our previous result on brain metastasis ability, we provide a characteristic metastasis profile of HER2-positive breast cancer cell lines in this study.
AB - Most studies on breast cancer metastasis have been performed using triple-negative breast cancer cells; thus, subtype-dependent metastatic ability of breast cancer is poorly understood. In this research, we performed intravenous injection (IVI) and intra-caudal arterial injections using nine human epidermal growth factor receptor-2 (HER2)-positive breast cancer cell lines for evaluating their metastatic abilities. Our results showed that MDA-MB-453, UACC-893, and HCC-202 had strong bone metastatic abilities, whereas HCC-2218 and HCC-1419 did not show bone metastasis. HER2-positive cell lines could hardly metastasize to the lung through IVI. From the genomic analysis, gene signatures were extracted according to the breast cancer subtypes and their metastatic preferences. The UACC-893 cell line was identified as a useful model for the metastasis study of HER2-positive breast cancer. Combined with our previous result on brain metastasis ability, we provide a characteristic metastasis profile of HER2-positive breast cancer cell lines in this study.
KW - Bone metastasis
KW - HER2-positive breast cancer
KW - In vivo imaging
KW - Lung metastasis
UR - http://www.scopus.com/inward/record.url?scp=85124034288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124034288&partnerID=8YFLogxK
U2 - 10.1007/s10585-022-10150-1
DO - 10.1007/s10585-022-10150-1
M3 - Article
C2 - 35103869
AN - SCOPUS:85124034288
SN - 0262-0898
VL - 39
SP - 467
EP - 477
JO - Clinical and Experimental Metastasis
JF - Clinical and Experimental Metastasis
IS - 3
ER -